We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -7.67 | -4.58% | 159.6218 | 167.46 | 157.65 | 167.26 | 10,721,784 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
AbbVie Inc. (ABBV) on Thursday said it is ending its research and development program for Rovalpituzumab Tesirine, or Rova-T, after the investigational antibody-drug conjugate showed no survival benefit in a phase 3 study in advanced small-cell lung cancer.
The North Chicago, Ill., biopharmaceutical company said it will prioritize other development programs within its oncology pipeline.
AbbVie said an independent data monitoring committee recommended terminating the study of Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer due to lack of survival benefit for patients receiving Rova-T compared with placebo.
Small-cell lung cancer is difficult to treat and accounts for 10% to 15% of all lung cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 29, 2019 09:19 ET (13:19 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
